An emerging, single-asset biopharma company will typically go on to build a portfolio of therapeutic assets to drive long-term success. Decision-making processes become much more complex as the company must now decide how to allocate resources across a range of potential therapies that may have distinct characteristics, address different markets, be in various stages of development, and exhibit different opportunities and risks.
The company’s “old” approaches and processes for optimizing a single asset are ill-suited to supporting strategic decisions across a diverse portfolio. In this paper, we address three key areas that companies often struggle with:
- Portfolio Forecasting – Holistically understanding the potential future value of a portfolio comprised of diverse assets
- Portfolio Prioritization – Effectively prioritizing individual assets within a portfolio and allocating resources accordingly
- Portfolio Reviews and Management – Systematically assessing the portfolio and adjusting decisions based on environmental or asset-specific changes
